FDA-регулируемый компонент
Этот компонент FDA одобрён или регулируется. Покупка без действительного рецепта может нарушить федеральное законодательство. Убедитесь, что вы соблюдаете все юридические требования в вашем регионе.
Liraglutide
Victoza / Saxenda
Liraglutide is a GLP-1 receptor agonist developed by Novo Nordisk, sharing 97% homology with native human GLP-1. It is FDA-approved as Victoza for type 2 diabetes management and as Saxenda for chronic weight management. As a once-daily injection, it was the first long-acting GLP-1 analog to achieve widespread clinical use and served as the predecessor to semaglutide.
Механизм действия
GLP-1 receptor agonist with 97% homology to native GLP-1. Enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying.
Протоколы исследований
Только для исследовательских целей. Не медицинская консультация.
Weight management protocols use up to 3.0mg daily with weekly 0.6mg dose escalation.
Примечания к исследованиям
Clinical Research Status
Liraglutide holds full FDA approval for two indications: type 2 diabetes (Victoza, approved 2010) and obesity (Saxenda, approved 2014). The LEADER cardiovascular outcomes trial demonstrated a 13% reduction in major adverse cardiovascular events. It remains widely prescribed though newer weekly agents are increasingly preferred.
Key Published Findings
The SCALE trials demonstrated 5-8% mean body weight loss versus placebo across multiple populations. Liraglutide has been shown to reduce HbA1c by 1.0-1.5% in type 2 diabetes, with additional benefits in beta-cell preservation. Post-marketing data from over a decade of use provides one of the most robust safety databases among GLP-1 agonists.
Safety Profile
The most common adverse effects are gastrointestinal: nausea, vomiting, and diarrhea, typically diminishing over 4-8 weeks of dose titration. A boxed warning exists for medullary thyroid carcinoma risk based on rodent studies, though human epidemiological data has not confirmed this risk. Pancreatitis cases have been reported rarely, and the drug is contraindicated in patients with personal or family history of MTC.
Comparison to Related Compounds
Compared to semaglutide, liraglutide requires daily rather than weekly injection and produces less weight loss (approximately 5-8% vs 15-17% body weight). It has a shorter half-life of 13 hours versus semaglutide's 7-day half-life, resulting in lower steady-state exposure. However, its longer track record provides greater long-term safety confidence for some clinicians.
Community Observations
Many users report that liraglutide's daily dosing allows more flexible appetite control timing compared to weekly injectables. The gradual dose titration schedule (0.6mg to 3.0mg over 4-5 weeks for obesity) helps mitigate GI side effects. Some practitioners still prefer it for patients who want the option to pause treatment quickly due to its shorter duration of action.
Половая жизнь
~13 hours
Реконституция
Pre-filled pen (no reconstitution)
Хранение
Лиофилизированный
Refrigerate 2-8C before first use.
Реконститутированный
Room temperature or refrigerate. Use within 30 days.
Юридический статус США
Также известен как
Последние исследования
Highlighting the role of peptides in regulating senescence-associated secretory phenotype (SASP) and inflammaging, with a focus on their potential as therapeutic agents for age-related cardiovascular diseases.
Highlighting the differential risk profiles of various GLP-1 receptor agonists for gastrointestinal adverse events based on real-world data, emphasizing implications for clinical practice.
Highlighting the comparative effectiveness and patient outcomes between once-weekly semaglutide and daily liraglutide for weight management in non-diabetic obese patients.
Часто задаваемые вопросы
Что такое Liraglutide?
Liraglutide is a GLP-1 receptor agonist developed by Novo Nordisk, sharing 97% homology with native human GLP-1. It is FDA-approved as Victoza for type 2 diabetes management and as Saxenda for chronic weight management. As a once-daily injection, it was the first long-acting GLP-1 analog to achieve widespread clinical use and served as the predecessor to semaglutide.
Как действует Liraglutide?
GLP-1 receptor agonist with 97% homology to native GLP-1. Enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying.
Каков регуляторный статус Liraglutide в США?
FDA-approved (Rx only)
Каков период полувыведения Liraglutide?
~13 hours
Как ещё называют Liraglutide?
Victoza, Saxenda
Peptide Contacts предоставляет исследовательские сводки только для информационных целей. Мы не хостим, распространяем или одобряем документацию поставщиков. Все сертификаты анализа, GMP-сертификаты и коммуникации с поставщиками должны быть запрослены и проверены непосредственно покупателем. Ничто на этом платформе не является юридическим, медицинским или профессиональным советом. Пользователи самостоятельно отвечают за проверку квалификаций поставщиков и обеспечение соответствия всем применимым местным, штатным и федеральным законам перед покупкой любых исследовательских химикатов. Использование этой платформы означает принятие полной личной ответственности.
Прочитать полное заявление о неприкосновенности